{"id":10468,"date":"2026-06-21T09:31:27","date_gmt":"2026-06-21T09:31:27","guid":{"rendered":"http:\/\/wp.frontsignals.com\/scopewires\/a-guide-to-the-new-medicare-glp-1-program\/"},"modified":"2026-06-21T09:31:27","modified_gmt":"2026-06-21T09:31:27","slug":"a-guide-to-the-new-medicare-glp-1-program","status":"publish","type":"post","link":"http:\/\/wp.frontsignals.com\/scopewires\/a-guide-to-the-new-medicare-glp-1-program\/","title":{"rendered":"A Guide To the New Medicare GLP-1 Program"},"content":{"rendered":"<div class='highlight_content'>\n<h2>Highlights<\/h2>\n<ul>\n<li>The Medicare GLP-1 Bridge Program offers eligible beneficiaries $50 monthly copayments for obesity medications.<\/li>\n<li>This initiative marks a significant shift towards permanent Medicare coverage for obesity treatment options.<\/li>\n<\/ul>\n<\/div>\n    <div id=\"afscontainer1\"><\/div>\n    \n<h2>Medicare GLP-1 Bridge Program Overview<\/h2>\n<p>The Medicare GLP-1 Bridge Program is a temporary initiative by the Centers for Medicare &amp; Medicaid Services (CMS) designed to provide eligible Medicare beneficiaries with access to glucagon-like peptide-1 receptor agonist (GLP-1) medications specifically for weight management from July 1, 2026, to December 31, 2027. This program represents a significant policy shift, as it allows access to medications for obesity treatment that have historically been excluded from Medicare coverage. Beneficiaries enrolled in Medicare Part D or Medicare Advantage plans can access these medications for a flat copayment of $50 per month, greatly reducing out-of-pocket costs compared to traditional Part D cost-sharing.<\/p>\n<div class=\"generated-table-wrapper\">\n<h5 class=\"table-title\">Comparison of Medicare GLP-1 Programs<\/h5>\n<table class=\"generated-table\">\n<thead>\n<tr>\n<th>Product\/Service<\/th>\n<th>Cost Estimation<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Monthly Subscription for GLP-1 Medications<\/td>\n<td>$800 &#8211; $1,200<\/td>\n<\/tr>\n<tr>\n<td>Annual Enrollment Fee for Medicare GLP-1 Program<\/td>\n<td>$0 &#8211; $200<\/td>\n<\/tr>\n<tr>\n<td>Out-of-Pocket Costs for Specialist Visits<\/td>\n<td>$100 &#8211; $300 per visit<\/td>\n<\/tr>\n<tr>\n<td>Diabetes Management Counseling Sessions<\/td>\n<td>$50 &#8211; $150 per session<\/td>\n<\/tr>\n<tr>\n<td>Home Monitoring Equipment for Diabetes<\/td>\n<td>$100 &#8211; $300<\/td>\n<\/tr>\n<tr>\n<td>Annual Blood Sugar Testing Supplies<\/td>\n<td>$50 &#8211; $150<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"table-disclaimer\">Prices, rates, and cost estimates in this article reflect the most recent information available but may vary over time. Please conduct independent research before making any financial decisions.<\/p>\n<\/div>\n<h2>Eligibility Criteria and Covered Medications<\/h2>\n<p>To qualify for the GLP-1 Bridge Program, beneficiaries must meet specific clinical requirements, primarily a body mass index (BMI) indicative of obesity, with those having a BMI of 30 or higher being eligible for coverage. Eligibility varies depending on the type of Medicare drug coverage plan, as those enrolled exclusively in certain plans are excluded unless they also hold a standalone Prescription Drug Plan (PDP). The medications covered under this program include FDA-approved GLP-1 drugs like Foundayo\u00ae, Wegovy\u00ae, and Zepbound\u00ae, which are indicated for chronic weight management in adults with obesity.<\/p>\n<h2>Cost and Payment Structure<\/h2>\n<p>The GLP-1 Bridge Program allows beneficiaries to access covered medications for a fixed copayment of $50 per month, which contrasts with standard medications that may involve higher coinsurance rates. Importantly, this copayment does not contribute to out-of-pocket maximums within Part D plans, nor does it count towards True Out-of-Pocket (TrOOP) costs. The requirement for prior authorization may also introduce delays, as prescribers must submit requests to a centralized CMS processor for claims to be approved.<\/p>\n<h2>Challenges and Implications<\/h2>\n<p>The program faces criticism for its limited duration and the exclusion of certain beneficiary groups, which may restrict access to necessary treatments for vulnerable populations. Challenges include the potential financial burden due to the $50 copayment not counting towards out-of-pocket limits and concerns over program sustainability given its 18-month timeframe. Stakeholders express apprehension about adherence to GLP-1 therapy, especially if beneficiaries perceive the program as temporary, which may affect long-term health outcomes.<\/p>\n<h2>Future Directions and Legislative Considerations<\/h2>\n<p>Looking forward, CMS has indicated plans to transition to the broader Medicare GLP-1 BALANCE Model, which would allow for more comprehensive participation from Medicare Part D plans and increased flexibility in pricing negotiations. Legislative initiatives, such as the Treat and Reduce Obesity Act of 2023, signal a growing momentum towards permanent coverage for obesity treatments under Medicare. These developments suggest that the landscape for obesity management within Medicare may evolve significantly, potentially enhancing patient access and addressing the public health challenge of obesity among the senior population.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Highlights The Medicare GLP-1 Bridge Program offers eligible beneficiaries $50 monthly copayments for obesity medications. This initiative marks a significant shift towards permanent Medicare coverage for obesity treatment options. Medicare GLP-1 Bridge Program Overview The Medicare GLP-1 Bridge Program is a temporary initiative by the Centers for Medicare &amp; Medicaid Services (CMS) designed to provide [&hellip;]<\/p>\n","protected":false},"author":34,"featured_media":10469,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[727],"class_list":["post-10468","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-api-post"],"_links":{"self":[{"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/posts\/10468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/comments?post=10468"}],"version-history":[{"count":0,"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/posts\/10468\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/media\/10469"}],"wp:attachment":[{"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/media?parent=10468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/categories?post=10468"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/wp.frontsignals.com\/scopewires\/wp-json\/wp\/v2\/tags?post=10468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}